In this in vitro study, changes in the activity of the neural membrane integral protein, ATPase, were recorded after the exposure of isolated synaptosomes to different concentrations of aluminium and lead. Both total ATPase activity and Mg2+-ATPase activity were studied. A specific mouse strain, heterozygous for a glial cell line-derived neurotrophic factor (GDNF), and the corresponding wild-type mouse cerebral tissue, were used for the synaptosome isolations. The ATPase activities of the GDNF+/– mouse synaptosomes were compared with those of wild-type synaptosomes. The decrease in total ATPase activity was similar in both types of synaptosomes, but after exposure to aluminium, the decrease of Mg2+-ATPase activity in the GDNF+/– synaptosomes was smaller than that in the wild-type synaptosomes. After exposure to lead, the protective effect of GDNF was not so clear. The synaptosomal effects of lead were already found at concentrations lower than those where cell toxicity appeared in SHSY5Y cell cultures. Thus, synaptosomal ATPase activity was considered to be a sensitive marker for the detection of lead-induced neurotoxicity.
ZhengW., AschnerM., & Ghersi-EgeaJ.F. (2003). Brain barrier systems: a new frontier in metal neurotoxicological research. Toxicology and Applied Pharmacology192, 1–11.
2.
GoyerR.A. (1993). Lead toxicity: current concerns. Environmental Health Perspectives100, 177–187.
3.
FlatenT.P. (2001). Aluminium as a risk factor in Alzheimer's disease, with emphasis on drinking water. Brain Research Bulletin55, 187–196.
4.
DedmanD.J., TreffryA., CandyJ.M., TaylorG.A., MorrisC.M., BloxhamC.A., PerryR.H., EdwardsonJ.A., & HarrisonP.M. (1992). Iron and aluminium in relation to brain ferritin in normal individuals and Alzheimer's-disease and chronic renal-dialysis patients. Biochemical Journal287, 509–514.
5.
ClaubergM., & JoshiJ.G. (1992). Effects of prolonged chronic dietary treatment with AlCl3 on selected metabolisms and memory in rats. Annals of the New York Academy of Science648, 289–290.
6.
AlfreyA.C. (1993). Aluminum toxicity in patients with chronic renal failure. Therapeutic Drug Monitoring15, 593–597.
7.
GoodP.F., & PerlD.P. (1993). Aluminium in Alzheimer's?Nature, London362, 418.
8.
GulyaK., RakonczayZ., & KasaP. (1990). Cholinotoxic effects of aluminum in rat brain. Journal of Neurochemistry54, 1020–1026.
9.
MoossyJ., ZubenkoG.S., MartinezA.J., RaoG.R., KoppU., & HaninI. (1989). Lateralization of brain morphologic and cholinergic abnormalities in Alzheimer's disease. Archives of Neurology46, 639–642.
10.
ExleyC., & BirchallJ.D. (1992). The cellular toxicity of aluminium. Journal of Theoretical Biology159, 83–98.
11.
TruppM., RydenM., JornvallH., FunakoshiH., TimmuskT., ArenasE., & IbanezC.F. (1995). Peripheral expression and biological activities of GDNF, a new neurotrophic factor for avian and mammalian peripheral neurons. Journal of Cell Biology130, 137–148.
12.
GhribiO., HermanM.M., ForbesM.S., DeWittD. A., & SavoryJ. (2001). GDNF protects against aluminium-induced apoptosis in rabbits by upregulating Bcl-2 and Bcl-XL and inhibiting mitochondrial Bax translocation. Neurobiology of Disease8, 764–773.
13.
HyppönenS., KohilaT., & TähtiH. (1993). The effects of cadmium, lead and aluminium on neural cell membrane adenosinetriphosphatase activity. Neuroscience Research Communications12, 77–83.
14.
KohilaT., HyppönenS., & TähtiH. (1995). The neurotoxicity of lead studied with the rat synaptosomal integral proteins ATPase and acetylcholinesterase. Neuroscience Research Communications16, 173–180.
15.
SaarmaM., & SariolaH. (1999). Other neurotrophic factors: glial cell line-derived neurotrophic factor (GDNF). Microscopy Research Technique45, 292–302.
16.
NagyA., & Delgado-EscuetaA.V. (1984). Rapid preparation of synaptosomes from mammalian brain using nontoxic isoosmotic gradient material (Percoll). Journal of Neurochemistry43, 1114–1123.
17.
PhillipsT.D., & HayesA.W. (1989). Principles and Methods of Toxicology.New York, NY, USA: Raven Press.
18.
LowryO.H., RosebroughN.J., FarrA.L., & RandellR.J. (1951). Protein measurement with the Folin phenol reagent. Journal of Biological Chemistry193, 265–275.
19.
BaldwinT.O. (1996). Firefly luciferase: the structure is known, but the mystery remains. Structure4, 223–228.
20.
DeLucaM., & McElroyW.D. (1974). Kinetics of the firefly luciferase catalyzed reactions. Biochemistry13, 921–925.
21.
GouldS.J., & SubramaniS. (1988). Firefly luciferase as a tool in molecular and cell biology. Analytical Biochemistry175, 5–13.
22.
TähtiH., EngelkeM., & VaalavirtaL. (1997). Mechanisms and models of neurotoxicity of n-hexane and related solvents. Archives of Toxicology19, Suppl. 1, 337–345.
23.
KakkoI., ToimelaT., & TähtiH. (2003). The synaptosomal membrane bound ATPase as a target for the neurotoxic effects of pyrethroids, permethrin and cypermethrin. Chemosphere51, 475–480.
24.
FatemiS.J., KadirF.H., & MooreG.R. (1991). Aluminium transport in blood serum: binding of aluminium by human transferrin in the presence of human albumin and citrate. Biochemical Journal280, 527–532.
25.
RostronC. (1982). Are we at risk from lead? Part I. Food and Chemical Toxicology20, 617–621.
26.
CarringtonC.D., & BolgerP.M. (1992). An assessment of the hazards of lead in food. Regulatory Toxicology and Pharmacology16, 265–272.
27.
MichaelsonI.A. (1973). Effects of inorganic lead on RNA, DNA and protein content in the developing neonatal rat brain. Toxicology and Applied Pharmacology26, 539–548.
28.
PetitT.L., LeBoutillierJ.C., & BrooksW. J. (1992). Altered sensitivity to NMDA following developmental lead exposure in rats. Physiology and Behaviour52, 687–693.
29.
SolheimL.P., & FrommH.J. (1980). A simple method for removing aluminum from adenosine-5′-triphosphate. Analytical Biochemistry109, 266–269.
30.
LaiJ.C., & BlassJ.P. (1984). Inhibition of brain glycolysis by aluminum. Journal of Neurochemistry42, 438–446.
31.
CrapperD.R., KrishnanS.S., & DaltonA.J. (1973). Brain aluminum distribution in Alzheimer's disease and experimental neurofibrillary degeneration. Science, New York180, 511–513.
32.
XuN., MajidiV., MarkesberyW.R., & EhmannW.D. (1992). Brain aluminium in Alzheimer's disease using an improved GFAAS method. Neurotoxicology13, 735–743.
33.
AiravaaraM., PiepponenM.S., AiraksinenM.S., SaarmaM., & AhteeL. (2002). Heterozygous GDNF knockout mice are more easily sensitized to repeated morphine than their wild type littermates. The Pharmacologist44, 2.
34.
AiravaaraM., GäddnäsH., PiepponenM.S., AiraksinenM.S., SaarmaM., & AhteeL. (2003). DeltaFosB expression is enhanced in heterozygous GDNF knockout mice after repeated morphine treatment. Behavioural Pharmacology14, Suppl. 1, 50.
